News & Podcast
Stay up to date with the latest stories, deep-dives and interviews from the Munich startup ecosystem. From funding deals to founder portraits and tech trends.
Mbiomics: 30 million euros in third series A closing
Fresh capital for innovative therapeutics: The Munich-based biotech startup Mbiomics secures funding to advance its microbiome therapies and drive the transition into the clinical phase.
Mbiomics: therapy revolution from the microbiome
The biotech startup Mbiomics wants to revolutionize microbiome-based therapies with an innovative TechBio platform. The goal: customized medicines with over 100 bacterial strains – against cancer, autoimmune, and neurodegenerative diseases. CEO and Co-Founder Johannes B. Woehrstein answered our questions.
Series A: €13 million for Mbiomics
Munich-based biotech company Mbiomics, which develops microbiome-based therapeutics, secures a Series A round of €13 million. In addition to Bayern Kapital, MIG Capital participated as lead investor, as did High-Tech Gründerfonds and additional private investors in the first closing of the round.
